Welcome to DailyUpdates Psychiatric, Addictive & Sleep Disorders channel - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Psychiatric, Addictive & Sleep Disorders channel



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Facebook

Today's journal articles

The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Siltuximab in Schizophrenia

Previous Journal Entries

5-HT6 receptor agonism facilitates emotional learning.

The effects of pioglitazone, a PPARĪ³ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.

Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.

FRAS1-related extracellular matrix 3 (FREM3) single-nucleotide polymorphism effects on gene expression, amygdala reactivity and perceptual processing speed: An accelerated aging pathway of depression risk.

Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.

Rational Design, Pharmacomodulation, Synthesis of Dual 5 - Hydroxytryptamine 7 (5 - HT7) / 5 - Hydroxytryptamine 2A (5 - HT2A) Receptors Antagonists and Evaluation by [(18)F] - PET Imaging in a Primate Brain.

Synthesis and Characterization of a Dual Kappa-Delta Opioid Receptor Agonist Analgesic Blocking Cocaine Reward Behavior.

Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

Disruption of glucocorticoid receptors in the noradrenergic system leads to BDNF up - regulation and altered serotonergic transmission associated with a depressive - like phenotype in female GR(DBHCre) mice.

Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2.

The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.

Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention.

Synthesis, nicotinic acetylcholine receptor binding, in vitro and in vivo pharmacology properties of 3' - (substituted pyridinyl) - deschloroepibatidine analogs.

The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia.

Ethylenedioxy homologs of N - methyl - (3,4 - methylenedioxyphenyl) - 2 - aminopropane (MDMA) and its corresponding cathinone analog methylenedioxymethcathinone: Interactions with transporters for serotonin, dopamine, and norepinephrine.

Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.

Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.

Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.

Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.

Today's News Items

Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN® (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose

Training Courses & Meetings

No events listed

Previous News Items

Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials